Back to Search

Insulin-Degludec,Liraglutide – Uses, Dosage, and Brands in UAE

Brand Name: XULTOPHY
Strength: 100 IU/ml,3.6 mg/ml | Form: Solution For Injection
Price in UAE: AED 1486.00
Available in UAE pharmacies

About Insulin-Degludec,Liraglutide

Class: | Combination of long-acting insulin (Insulin Degludec) and GLP-1 receptor agonist (Liraglutide) Use: | Indicated for the treatment of adults with type 2 diabetes mellitus to improve glycemic control in conjunction with diet and exercise Adult dose: | Starting dose is typically 16 units (16 IU of Insulin Degludec and 0.58 mg of Liraglutide) once daily; dose may be adjusted based on individual blood glucose levels Pediatric dose: | Safety and efficacy have not been established in ped

Drug Class

Combination of long-acting insulin (Insulin Degludec) and GLP-1 receptor agonist (Liraglutide)

Uses & Indications

Indicated for the treatment of adults with type 2 diabetes mellitus to improve glycemic control in conjunction with diet and exercise

Storage Requirements

Store in a refrigerator (2°C to 8°C); may be kept at room temperature (up to 30°C) for up to 21 days after first use; do not freeze

Manufacturer & Packaging

Manufacturer: Novo Nordisk A/S, DENMARK

Package Size

3ml Pre-Filled Pens x 5

Price & Supplier

Price in UAE: AED 1486.00

Dosage Information

Adult Dose

Starting dose is typically 16 units (16 IU of Insulin Degludec and 0.58 mg of Liraglutide) once daily; dose may be adjusted based on individual blood glucose levels

Pediatric Dose

Safety and efficacy have not been established in pediatric patients; not recommended for use in children

Side Effects

Common side effects include hypoglycemia, nausea, vomiting, diarrhea, decreased appetite, and injection site reactions

Contraindications & Precautions

Contraindicated in patients with a history of hypersensitivity to Insulin Degludec, Liraglutide, or any of the excipients; also contraindicated in patients with diabetic ketoacidosis

Important Warnings

Risk of serious hypoglycemia, particularly when used with other antidiabetic medications; potential risk of thyroid C-cell tumors; pancreatitis risk; renal impairment may affect drug clearance; monitor renal function regularly

Medical Disclaimer

This information is for educational purposes only and should not replace professional medical advice. Always consult with a licensed healthcare provider or pharmacist in the UAE before taking any medication. The information presented here is specific to medicines available in UAE pharmacies and is regularly updated to ensure accuracy for patients and healthcare professionals in the United Arab Emirates.

View All Combination of long-acting insulin (Insulin Degludec) and GLP-1 receptor agonist (Liraglutide) Medicines Browse All Categories